---
url: https://www.servicesaustralia.gov.au/leukaemia-chronic-lymphocytic-leukaemia
title: Leukaemia - chronic lymphocytic leukaemia - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:41:01.542Z
source: servicesaustralia.gov.au
---
# Leukaemia - chronic lymphocytic leukaemia

The Pharmaceutical Benefits Scheme (PBS) subsidises idelalisib for patients with chronic lymphocytic leukaemia (CLL).

## on this page

-   [Patient eligibility](#a1)
-   [Authority applications](#a2)
-   [More information](#a3)

## Patient eligibility

The PBS subsidises treatment with idelalisib under the _National Health Act 1953_, section 85 for patients with CLL.

Patients must be eligible for the [PBS](/pharmaceutical-benefits-scheme) and meet the relevant restriction criteria.

The [Schedule of Pharmaceutical Benefits](http://www.pbs.gov.au/pbs/home;jsessionid=1dlcoha0l4vz2eo3rw03twopu) on the PBS website outlines the restrictions for prescribing idelalisib.

## Authority applications

### Applying for initial treatment

To apply for initial authority approval to prescribe PBS-subsidised idelalisib to treat CLL either:

-   use [Online PBS Authorities in HPOS](/apply-for-pbs-authority?context=20)
-   call the [PBS authority approvals line](/health-professionals-contact-information?context=20#pbsauthority).

### Applying for continuing treatment

To apply for continuing authority approval to prescribe PBS-subsidised idelalisib to treat CLL either:

-   use [Online PBS Authorities in HPOS](/apply-for-pbs-authority?context=20)
-   call the [PBS authority approvals line](/health-professionals-contact-information?context=20#pbsauthority).

## More information

Call the [PBS authority approvals line](/health-professionals-contact-information?context=20#pbsauthority) for further information.
